Viking Therapeutics, Inc. Research and Development Expense
Viking Therapeutics, Inc. (VKTX) reported Research and Development Expense of $115.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-29
- Viking Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $115.75M, a 92.43% increase year-over-year.
- Viking Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $150.15M, a 262.76% increase year-over-year.
- Viking Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $153.46M, a 395.24% increase year-over-year.
- Viking Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $89.95M, a 294.79% increase year-over-year.
- Viking Therapeutics, Inc. research and development expense for fiscal 2025 was $344.95M, a 239.38% increase from fiscal 2024.
- Viking Therapeutics, Inc. research and development expense for fiscal 2024 was $101.64M, a 59.30% increase from fiscal 2023.
- Viking Therapeutics, Inc. research and development expense for fiscal 2023 was $63.81M, a 17.65% increase from fiscal 2022.
- Viking Therapeutics, Inc. research and development expense for fiscal 2022 was $54.23M, a 20.57% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $115.75M 10-Q · filed 2026-07-29 | $265.90M 10-Q · filed 2026-07-29 | $419.36M derived: sum of 3 quarters · filed 2026-07-29 | $509.32M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $150.15M 10-Q · filed 2026-04-30 | $303.61M derived: sum of 2 quarters · filed 2026-04-30 | $393.56M derived: sum of 3 quarters · filed 2026-04-30 | $453.71M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $153.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $243.41M derived: sum of 2 quarters · filed 2026-02-11 | $303.56M derived: sum of 3 quarters · filed 2026-07-29 | $344.95M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $89.95M 10-Q · filed 2025-10-23 | $150.11M derived: sum of 2 quarters · filed 2026-07-29 | $191.50M 10-Q · filed 2025-10-23 | $222.48M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $60.15M 10-Q · filed 2026-07-29 | $101.54M 10-Q · filed 2026-07-29 | $132.53M derived: sum of 3 quarters · filed 2026-07-29 | $155.32M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $41.39M 10-Q · filed 2026-04-30 | $72.38M derived: sum of 2 quarters · filed 2026-04-30 | $95.16M derived: sum of 3 quarters · filed 2026-04-30 | $118.93M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $30.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $53.77M derived: sum of 2 quarters · filed 2026-02-11 | $77.54M derived: sum of 3 quarters · filed 2026-02-11 | $101.64M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $22.79M 10-Q · filed 2025-10-23 | $46.55M derived: sum of 2 quarters · filed 2025-10-23 | $70.66M 10-Q · filed 2025-10-23 | $91.16M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $23.77M 10-Q · filed 2025-07-23 | $47.87M 10-Q · filed 2025-07-23 | $68.37M derived: sum of 3 quarters · filed 2026-02-11 | $86.75M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $24.10M 10-Q · filed 2025-04-24 | $44.60M derived: sum of 2 quarters · filed 2026-02-11 | $62.98M derived: sum of 3 quarters · filed 2026-02-11 | $76.90M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $20.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $38.88M derived: sum of 2 quarters · filed 2026-02-11 | $52.80M derived: sum of 3 quarters · filed 2026-02-11 | $63.81M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $18.38M 10-Q · filed 2024-10-23 | $32.30M derived: sum of 2 quarters · filed 2024-10-23 | $43.30M 10-Q · filed 2024-10-23 | $59.48M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $13.92M 10-Q · filed 2024-07-24 | $24.93M 10-Q · filed 2024-07-24 | $41.10M derived: sum of 3 quarters · filed 2025-02-26 | $53.06M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | $11.01M 10-Q · filed 2024-04-25 | $27.19M derived: sum of 2 quarters · filed 2025-02-26 | $39.15M derived: sum of 3 quarters · filed 2025-02-26 | $52.69M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $16.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $28.14M derived: sum of 2 quarters · filed 2025-02-26 | $41.68M derived: sum of 3 quarters · filed 2025-02-26 | $54.23M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $11.96M 10-Q · filed 2023-10-25 | $25.50M derived: sum of 2 quarters · filed 2023-10-25 | $38.06M 10-Q · filed 2023-10-25 | $47.90M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-06-30 | $13.54M 10-Q · filed 2023-07-26 | $26.10M 10-Q · filed 2023-07-26 | $35.94M derived: sum of 3 quarters · filed 2024-02-07 | $46.74M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-03-31 | $12.55M 10-Q · filed 2023-04-26 | $22.40M derived: sum of 2 quarters · filed 2024-02-07 | $33.20M derived: sum of 3 quarters · filed 2024-02-07 | $46.00M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2021-12-31 | $9.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $20.64M derived: sum of 2 quarters · filed 2024-02-07 | $33.45M derived: sum of 3 quarters · filed 2024-02-07 | $44.98M 10-K · filed 2024-02-07 | ||||
| 2021-09-30 | $10.79M 10-Q · filed 2022-10-26 | $23.60M derived: sum of 2 quarters · filed 2022-10-26 | $35.13M 10-Q · filed 2022-10-26 | $44.18M derived: sum of 4 quarters · filed 2022-10-26 | ||||
| 2021-06-30 | $12.80M 10-Q · filed 2022-07-27 | $24.34M 10-Q · filed 2022-07-27 | $33.39M derived: sum of 3 quarters · filed 2022-07-27 | $40.50M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-03-31 | $11.54M 10-Q · filed 2022-04-27 | $20.58M derived: sum of 2 quarters · filed 2022-04-27 | $27.70M derived: sum of 3 quarters · filed 2022-04-27 | $35.48M derived: sum of 4 quarters · filed 2022-04-27 | ||||
| 2020-12-31 | $9.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $16.16M derived: sum of 2 quarters · filed 2022-02-09 | $23.95M derived: sum of 3 quarters · filed 2022-02-09 | $31.93M 10-K · filed 2022-02-09 | ||||
| 2020-09-30 | $7.12M 10-Q · filed 2021-11-03 | $14.90M derived: sum of 2 quarters · filed 2021-11-03 | $22.88M 10-Q · filed 2021-11-03 | $29.33M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $7.78M 10-Q · filed 2021-07-28 | $15.77M 10-Q · filed 2021-07-28 | $22.22M derived: sum of 3 quarters · filed 2021-07-28 | $27.50M derived: sum of 4 quarters · filed 2021-07-28 | ||||
| 2020-03-31 | $7.99M 10-Q · filed 2021-04-28 | $14.44M derived: sum of 2 quarters · filed 2021-04-28 | $19.72M derived: sum of 3 quarters · filed 2021-04-28 | $27.05M derived: sum of 4 quarters · filed 2021-04-28 | ||||
| 2019-12-31 | $6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $11.73M derived: sum of 2 quarters · filed 2021-02-17 | $19.06M derived: sum of 3 quarters · filed 2021-02-17 | $23.56M 10-K · filed 2021-02-17 | ||||
| 2019-09-30 | $5.28M 10-Q · filed 2020-10-28 | $12.61M derived: sum of 2 quarters · filed 2020-10-28 | $17.11M 10-Q · filed 2020-10-28 | $22.20M derived: sum of 4 quarters · filed 2020-10-28 | ||||
| 2019-06-30 | $7.33M 10-Q · filed 2020-07-29 | $11.83M 10-Q · filed 2020-07-29 | $16.92M derived: sum of 3 quarters · filed 2020-07-29 | $22.61M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | $4.50M 10-Q · filed 2020-04-30 | $9.59M derived: sum of 2 quarters · filed 2020-04-30 | $15.27M derived: sum of 3 quarters · filed 2020-04-30 | $20.49M derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $10.78M derived: sum of 2 quarters · filed 2020-02-26 | $16.00M derived: sum of 3 quarters · filed 2020-02-26 | $19.04M 10-K · filed 2020-02-26 | ||||
| 2018-09-30 | $5.69M 10-Q · filed 2019-11-05 | $10.91M derived: sum of 2 quarters · filed 2019-11-05 | $13.95M 10-Q · filed 2019-11-05 | $16.98M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $5.22M 10-Q · filed 2019-08-01 | $8.26M 10-Q · filed 2019-08-01 | $11.30M derived: sum of 3 quarters · filed 2019-08-01 | $14.76M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | $3.04M 10-Q · filed 2019-05-02 | $6.08M derived: sum of 2 quarters · filed 2019-05-02 | $9.54M derived: sum of 3 quarters · filed 2019-05-02 | $13.26M derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $6.50M derived: sum of 2 quarters · filed 2019-03-13 | $10.21M derived: sum of 3 quarters · filed 2019-03-13 | $13.74M 10-K · filed 2019-03-13 | $13.74M 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $3.46M 10-Q · filed 2018-11-07 | $3.46M 10-Q · filed 2017-11-08 | $7.18M derived: sum of 2 quarters · filed 2018-11-07 | $10.71M 10-Q · filed 2018-11-07 | $10.71M 10-Q · filed 2017-11-08 | $13.36M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | $3.72M 10-Q · filed 2018-08-09 | $3.72M 10-Q · filed 2017-08-09 | $7.24M 10-Q · filed 2018-08-09 | $7.24M 10-Q · filed 2017-08-09 | $9.89M derived: sum of 3 quarters · filed 2018-08-09 | $12.00M derived: sum of 4 quarters · filed 2018-08-09 | ||
| 2017-03-31 | $3.53M 10-Q · filed 2018-05-09 | $3.53M 10-Q · filed 2017-05-10 | $6.18M derived: sum of 2 quarters · filed 2018-05-09 | $8.28M derived: sum of 3 quarters · filed 2018-05-09 | $10.65M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2016-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $4.75M derived: sum of 2 quarters · filed 2018-03-07 | $7.12M derived: sum of 3 quarters · filed 2018-03-07 | $9.00M 10-K · filed 2018-03-07 | ||||
| 2016-09-30 | $2.10M 10-Q · filed 2017-11-08 | $4.48M derived: sum of 2 quarters · filed 2017-11-08 | $6.35M 10-Q · filed 2017-11-08 | $9.57M derived: sum of 4 quarters · filed 2017-11-08 | ||||
| 2016-06-30 | $2.37M 10-Q · filed 2017-08-09 | $4.25M 10-Q · filed 2017-08-09 | $7.47M derived: sum of 3 quarters · filed 2017-08-09 | $9.98M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | $1.88M 10-Q · filed 2017-05-10 | $5.10M derived: sum of 2 quarters · filed 2017-05-10 | $7.60M derived: sum of 3 quarters · filed 2017-05-10 | $8.71M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $5.73M derived: sum of 2 quarters · filed 2017-03-21 | $6.83M derived: sum of 3 quarters · filed 2017-03-21 | $6.97M 10-K · filed 2017-03-21 | ||||
| 2015-09-30 | $2.51M 10-Q · filed 2016-11-10 | $3.61M derived: sum of 2 quarters · filed 2016-11-10 | $3.75M 10-Q · filed 2016-11-10 | $3.89M derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $1.10M 10-Q · filed 2016-08-11 | $1.24M 10-Q · filed 2016-08-11 | $1.38M derived: sum of 3 quarters · filed 2016-08-11 | $2.17M derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $138.97K 10-Q · filed 2016-05-10 | $281.76K derived: sum of 2 quarters · filed 2016-05-10 | $1.07M derived: sum of 3 quarters · filed 2016-05-10 | $22.31M derived: sum of 4 quarters · filed 2016-05-10 | ||||
| 2014-12-31 | $142.79K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $931.43K derived: sum of 2 quarters · filed 2016-03-08 | $22.17M derived: sum of 3 quarters · filed 2016-03-08 | $22.22M 10-K · filed 2016-03-08 | ||||
| 2014-09-30 | $788.65K 10-Q · filed 2015-11-05 | $22.03M derived: sum of 2 quarters · filed 2015-11-05 | $22.08M 10-Q · filed 2015-11-05 | |||||
| 2014-06-30 | $21.24M 10-Q · filed 2015-08-14 | $21.29M 10-Q · filed 2015-08-14 | ||||||
| 2014-03-31 | $50.00K 10-Q · filed 2015-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |